TPG Biotech previously invested $12.8m in the business alongside its angel investors.
Trevi recently released data from Phase 1 trial in which Nalbuphine ER was shown to be well tolerated in patients on hemodialysis with itch and established proof-of-concept in uremic pruritus.
The company plans to initiate trials in two severe itch conditions, uremic pruritus and prurigo nodularis, in the third quarter of this year, and expects to have top-line results in the second half of 2015.
TPG Biotech managing director Eran Nadav said, “We have been very pleased with the progress the Trevi team has made in rapidly advancing Nalbuphine ER for chronic pruritus.
“Chronic pruritus is a significant unmet medical need, and we believe that mechanistically, and based on the recent data generated in the Phase 1 trial, Nalbuphine ER has a good chance of providing safe and effective therapy for these patients.”
Copyright © 2014 AltAssets